Peptides
Evidence: animal_plus_anecdotal
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Standard: Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
Loading: Research indicates a loading phase of 5-10 mg per week (split into 2 doses) for the first 4-6 weeks.
Maintenance: Research indicates 2-5 mg every 1-2 weeks after loading phase completion.
Administration: subcutaneousintramuscular
Timing: No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Duration: Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
TB-500 is a systemic peptide — unlike BPC-157, injection location does not need to be near the injury. The BPC-157 + TB-500 healing stack provides complementary mechanisms: BPC-157 for local vascular repair and TB-500 for systemic actin-mediated tissue remodeling. Thymosin Beta-4 was shown to increase re-epithelialization by 42% over controls at 4 days and 61% at 7 days post-wounding. TB-500 is banned by WADA.
Compounding pharmacy (503A/503B) or research-grade supplier with COA. Store lyophilized at -20C; reconstituted at 2-8C.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →